Linvoseltamab

• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens … Pending
  2024-519504-27-00 Phase III 10 countries Regeneron Pharmaceuticals Inc.
• A Trial to Study if REGN17372 in Combination with Linvoseltamab is Tolerable for Adult Participants with Relapsed/Refractory Multiple Myelom… Pending
  2025-522776-93-00 Phase I 1 country Regeneron Pharmaceuticals Inc.
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab… Recruiting
  2024-519827-16-00 Phase III 16 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A proof-of-concept study to learn whether linvoseltamab can eliminate abnormal plasma cells that may lead to multiple myeloma in adult patie… Recruiting
  2023-505242-25-00 Phase II 6 countries Regeneron Pharmaceuticals Inc.
• A Window of Opportunity Trial To Learn If Linvoseltamab Is Safe And Well Tolerated, And How Well It Works In adult Participants With Recentl… Recruiting
  2022-500800-24-00 Phase II 2 countries Regeneron Pharmaceuticals Inc.
• A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Recruiting
  2023-507809-34-00 Phase I/II 2 countries Regeneron Pharmaceuticals Inc.
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting
  2024-511454-45-00 Phase I (FiH) 2 countries Regeneron Pharmaceuticals Inc.
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended
  2022-501396-62-00 Phase III 7 countries Regeneron Pharmaceuticals Inc.

Showing 1–8 of 8 trials